Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
Patent 5350756 Issued on September 27, 1994. Estimated Expiration Date: 
May 28, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
May 28, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesMethod for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders Patent #: 5166207 InventorApplicationNo. 890432 filed on 05/28/1992US Classes:514/289, Two of the cyclos share at least three ring members (i.e., bridged) (e.g., morphinans, etc.)514/295, Two of the cyclos share at least three ring carbons (i.e., bridged) (e.g., benzomorphans, etc.)514/305Quinuclidines (including unsaturation)ExaminersPrimary: Cintins, Marianne M.Assistant: Criares, T. J. Attorney, Agent or FirmInternational ClassA61K 031/44AbstractThis invention discloses a method for increasing the effectiveness of dextromethorphan (DM) as an antitussive agent (i.e., as a cough suppressant). This method involves the concurrent administration of DM and a second agent which inhibits the oxidative activity of debrisoquin hydroxylase, a cytochrome P450 oxidase enzyme. Effective anti-oxidant compounds include quinidine, yohimbine, and fluoxetine.Other References
| |
